[Comment] Encouraging results but questions remain for dengue vaccine

Dengue has expanded dramatically over the past several decades, with the four dengue virus serotypes (DENV-1 –4) now co-circulating in most dengue-endemic regions.1 A safe and efficacious vaccine will be a crucial element of comprehensive global prevention and control. In The Lancet Infectious Diseases, Xavier Sáez-Llorens and colleagues2 report 18-month interim results from a phase 2 trial of a live at tenuated tetravalent dengue vaccine candidate, TDV (Takeda, Osaka, Japan). TDV was administered in either one or two doses separated by 3 or 12 months in 1800 participants aged 2–17 years in three dengue-endemic countries: Dominican Republic, Panama, and Philippines.
Source: The Lancet Infectious Diseases - Category: Infectious Diseases Authors: Tags: Comment Source Type: research